← BackPenumbra Inc · Surgical & Medical Instruments & ApparatusPEN
Low riskNext report: Around Nov 4 (est.)
The short versionA profitable company with growing sales.
Going well
- Sales up 15% in the latest quarter vs a year ago
- Profitable
- Sales up 18% last year
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 1.1% to their holdings in the quarter ending June 2026 (182 bought, 251 sold)
- Held by Ray Dalio (Bridgewater)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$325.08+0.1% that day
- Company value
- $12.8B
- Share price times all shares
- Price vs profit (P/E)
- 79.9x
- You pay about $80 for each $1 of yearly profit
- Price vs sales
- 8.5x
- Company value is 8.5 times a year of sales
- Cash vs value
- 2%
- Cash as a share of company value
From PEN's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$390.0M+15% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $1.5B, up 18% from the 12 months before. Over 5 years, sales grew about 20% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.13.8%
- PassDebt under half of equityNot relying on borrowed money.No debt reported
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.12.7%
- MissProfitable every yearSteady profits, not one good year.8 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$174.9M
- MissShare count not growingNot diluting owners. Falling means buybacks.+3.8% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.67.1%
- Revenue
- $1.4B
- +17.5% vs prior year
- 5-year growth
- +20.2%/yr
- revenue, per year
- Total debt
- None
- 0.00x equity
- Current ratio
- 6.64x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $390.0M
- +14.9% YoY
- EPS
- $0.88
- vs $1.15
- Op. margin
- 10.5%
- -1.5 pts
- Gross margin
- 67.9%
- +1.9 pts
- Free cash flow
- $32.5M
- Share count
- +0.8%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 0.5
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+1.1%Institutions added 1.1% to their holdings. 182 bought, 251 sold.
Shares held by institutions34.1M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+0.8%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
No debt reportedShares outstandingLatest reported
39MNext reportAround Nov 4 (est.)Estimated from the same quarter last year
- Results filedJul 30
- Results filedMay 6
- Results filedFeb 25
- Results filedJan 15
- Results filedNov 5, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.